Tag: Biosynex
Biosynex declines by 53% in 2023 post-Covid-19
(AOF) – Biosynex announces 2023 turnover down 53% to 93 million euros with “a share of Covid products becoming minimal”. The diagnostic specialist posted a net loss, group share of…
Biosynex optimistic after its post-Covid transition
(AOF) – Biosynex lost 4.87% to 8.20 euros after publishing sharply falling annual revenues. 2023 turnover fell 53% to 93.1 million euros. This decline in the rapid test specialist must,…
COMPLETION OF THE FUSION-ABSORPTION OF THERADIAG BY BIOSYNEX – 12/20/2023 at 6:00 p.m.
Strasbourg and Croissy-Beaubourg, December 15, 2023 – 6:00 p.m. CET – BIOSYNEX and THERADIAG announce that the extraordinary general meetings of shareholders of THERADIAG SA (Euronext Paris: ALTER) and BIOSYNEX…
Completion of the merger absorption of Theradiag by Biosynex
By Hector Chaunu Published on 12/15/2023 at 6:06 p.m. Photo credit © ChaunuPictures (Boursier.com) — BIOSYNEX and THERADIAG…
Biosynex: achievement of Theradiag absorption – 12/15/2023 at 6:28 p.m.
(AOF) – Biosynex and Theradiag announce that their extraordinary general meetings met this Friday and approved the merger-absorption of Theradiag by Biosynex, on the basis of an exchange ratio of…
Biosynex: achieving Theradiag absorption
(AOF) – Biosynex and Theradiag announce that their extraordinary general meetings met this Friday and approved the merger-absorption of Theradiag by Biosynex, on the basis of an exchange ratio of…
Biosynex: the FDA grants the first authorizations to ProciseDx for its therapeutic monitoring tests for biological drugs
By Alexandra Saintpierre Published on 02/10/2023 at 3:53 p.m. Photo credit © Biosynex (Boursier.com) — ProciseDx Inc., which…
Biosynex: Theradiag absorption merger project approved – 09/29/2023 at 6:31 p.m.
(AOF) – The Boards of Directors of Biosynex, specialized in the design, distribution and marketing of in vitro diagnostic devices, and of Theradiag, specialized in in vitro diagnostics, unanimously approved…
Biosynex: Theradiag absorption merger project approved
(AOF) – The Boards of Directors of Biosynex, specialized in the design, distribution and marketing of in vitro diagnostic devices, and of Theradiag, specialized in in vitro diagnostics, unanimously approved…
Biosynex: Consolidated net profit taking into account cyclical depreciation of stocks of Covid-19 products
(Boursier.com) — BIOSYNEX’s turnover for the first half of 2023 stood at €42.7 million, down €99.5 million compared to the same period of the previous year. As expected, the Group…
Biosynex: acquires Innoxa’s eye care business – 06/08/2023 at 18:11
(CercleFinance.com) – Biosynex announces the acquisition of the ‘eye care’ activity of Innoxa laboratories, thus strengthening the division of the Biosynex group and opening up a new market, that of…
Biosynex: acquires the eye care business of Innoxa
(CercleFinance.com) – Biosynex announces the acquisition of the ‘eye care’ activity of Innoxa laboratories, thus strengthening the division of the Biosynex group and opening up a new market, that of…